BioMarin PharmaceuticalBMRN -0.34%71 PB Ratio is 1.83 as of Jul. 06, 2026, which is 51% below its 10-year median of 3.77. GuruFocus rates BMRN with a GF Score™ of 71/100 and a GF Value™ of $87.81 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,230 Biotechnology companies, BioMarin Pharmaceutical ranks better than 66.02% on this metric.
The historical rank and industry rank for BioMarin Pharmaceutical's PB Ratio or its related term are showing as below:
BMRN'
s PB Ratio Range Over the Past 10 Years
Min: 1.61 Med: 3.77 Max: 8.47
Current: 1.83
During the past 13 years, BioMarin Pharmaceutical's highest PB Ratio was 8.47. The lowest was 1.61. And the median was 3.77.
BMRN's PB Ratio is ranked better than 66.02% of 1230
companies
in the Biotechnology industry
Industry Median: 2.99
vs BMRN: 1.83
During the past 12 months, BioMarin Pharmaceutical's average Book Value Per Share Growth Rate was 6.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 8.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 7.40% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 8.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of BioMarin Pharmaceutical was 53.30% per year. The lowest was -13.40% per year. And the median was 12.50% per year.
Back to Basics: PB Ratio
BioMarin Pharmaceutical (NAS:BMRN) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioMarin Pharmaceutical's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioMarin Pharmaceutical PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's PB Ratio distribution charts can be found below:
* The bar in red indicates where BioMarin Pharmaceutical's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
BioMarin Pharmaceutical (BMRN) has a PB Ratio of 1.83 as of Jul. 06, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BioMarin Pharmaceutical and its competitors. This is 51% below median its historical median of 3.77. Over the past decade, BioMarin Pharmaceutical's PB Ratio has ranged from 1.61 to 8.47. According to the industry distribution chart, BioMarin Pharmaceutical ranks #418 out of 1230 companies in the Biotechnology industry, placing it in the top 34%.
Is BioMarin Pharmaceutical's PB Ratio too high?
BioMarin Pharmaceutical's current PB Ratio of 1.83 is 51% below median its 10-year median of 3.77. Over the past 10 years, this metric has ranged from a low of 1.61 to a high of 8.47. The Biotechnology industry median PB Ratio is 2.99. BioMarin Pharmaceutical's value of 1.83 is 38.8% below this industry median. Based on the distribution chart, BioMarin Pharmaceutical ranks #418 out of 1230 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioMarin Pharmaceutical has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's PB Ratio compare to CYTK and ARWR?
According to the Biotechnology industry distribution chart, BioMarin Pharmaceutical ranks #418 out of 1230 companies for PB Ratio. This puts BioMarin Pharmaceutical in the upper half of its industry. The industry median PB Ratio is 2.99. BioMarin Pharmaceutical's value of 1.83 is 38.8% below this benchmark. Historically, BioMarin Pharmaceutical's own PB Ratio has ranged from 1.61 to 8.47 over the past decade. While the company's 10-year median is 3.77 vs. the industry median of 2.99, BioMarin Pharmaceutical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.99, based on 1,230 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioMarin Pharmaceutical's current PB Ratio of 1.83 is 38.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BioMarin Pharmaceutical and its competitors. For the Biotechnology industry, the median PB Ratio is 2.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioMarin Pharmaceutical's current PB Ratio is 1.83, which is 51% below median its own 10-year median of 3.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (BMRN) is currently considered Significantly Undervalued. The stock's GF Value™ is $87.81, compared to a current price of $58.79 — trading 33% below its estimated fair value. The current PB Ratio is 1.83, which is 51% below median its 10-year median of 3.77 and 38.8% below the Biotechnology industry median of 2.99. BioMarin Pharmaceutical's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For BioMarin Pharmaceutical (BMRN), the current PB Ratio is 1.83 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioMarin Pharmaceutical (BMRN) Overvalued in 2026?
Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued.
The current stock price of $58.79 is trading 33% below its estimated GF Value™ of $87.81.
GuruFocus considers BioMarin Pharmaceutical to be Significantly Undervalued.
Key valuation signals for BMRN:
PB Ratio: 1.83 (51% below median its 10-year median of 3.77)
GF Value™: $87.81 vs. price of $58.79 (33% below fair value)
Industry Position: 38.8% below the Biotechnology median (#418 of 1230)
No single metric tells the full story. See the BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
71GF Score
Get the complete analysis for BMRN
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMRN has been successfully added to your 
